CEREVEL ALERT: Is $45 Per Share Too Low for Cerevel (Nasdaq: CERE)? BFA Law is Investigating and Urges Shareholders to Contact the Firm About Your Rights

Core Viewpoint - Cerevel Therapeutics is set to be acquired by AbbVie for $45.00 per share, valuing the company at approximately$8.7 billion, with the transaction expected to close in mid-2024 [1] Company Summary - AbbVie will acquire all outstanding shares of Cerevel Therapeutics for a cash price of $45.00 per share [1] - The total equity value of the transaction is around$8.7 billion [1] - The boards of directors of both companies have approved the acquisition [1] - The expected closing date for the transaction is in the middle of 2024 [1] Legal Investigation - Bleichmar Fonti & Auld LLP is investigating the merger, suggesting potential conflicts of interest within Cerevel Therapeutics' board of directors [9] - The law firm believes the process was unfair and the amount agreed upon for shareholders may also be unfair [9] - Current shareholders of Cerevel Therapeutics are encouraged to submit their information to understand their rights [9]